Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs
Trends of Business-to-Business Transactions to Develop Innovative Cancer Drugs
复制标题
DOI：
10.3390/su12145535
复制
发表时间：
2020-07-01
期刊：
影响因子：
3.9
通讯作者：
Kodama, Kota
中科院分区：
文献类型：
--
作者：
Djurian, Arisa;Makino, Tomohiro;Kodama, Kota
制药行业的一个关键概念是开放式创新，制药公司通过获取外部知识为人类健康做出贡献，并适应不断变化的商业环境。由于成功的药物发现和开发变得具有挑战性，制药公司必须通过各种公司间伙伴关系积极寻求新药的开放式创新，以提高可持续性。本研究旨在通过考察美国食品药品监督管理局（FDA）批准的抗癌药物相关企业间交易，解释抗癌药物开发中企业间合作的趋势，并评估其有效性。这是一种新颖的方法，在每个产品上而不是在公司层面上实施这一点。调查结果显示，过去20年来，肿瘤领域的公司间交易数量有所增加。此外，自2015年以来，与生物制剂相关的年度交易数量已超过小分子，主要由三种PD-（L）1抑制剂驱动：Keytruda，Opdivo和Tecentriq。此外，与生物制剂相关的企业间交易的平均数量在总量、联盟和融资方面明显高于小分子，这表明生物抗癌药物的企业间交易通过各种方式活跃地发生。此外，交易数量与生物制品批准适应症的平均数量之间存在正相关和显著相关性，但对于小分子而言则不然。这些结果表明，观察到的活跃的公司间交易的趋势是关键，在增加癌症药物的研究和开发的成功概率。这可能为成功开发创新候选药物以解决未满足的医疗需求提供该行业的潜在突破。有必要进一步研究，以确认这种模式在更广泛的药物发现和开发的适用性。
A key concept in the pharmaceutical industry is open innovation, in which pharmaceutical companies contribute to human health and adapt to a changing business environment by acquiring external knowledge. As successful drug discoveries and developments have become challenging, pharmaceutical companies must proactively pursue the open innovation of new drugs through various inter-firm partnerships to be more sustainable. This study aims to interpret the trend of inter-firm partnerships in the development of cancer drugs and to evaluate their effectiveness by examining inter-firm transactions related to cancer drugs approved by the US Food and Drug Administration (FDA). It is a novel approach to exercise this on each product instead of at the company level. The findings revealed that the number of inter-firm transactions in the oncology field has increased over the past 20 years. Furthermore, the annual number of transactions related to biologics has surpassed that of small molecules since 2015 and has been primarily driven by three PD-(L)1 inhibitors: Keytruda, Opdivo, and Tecentriq. Moreover, the average number of inter-firm transactions related to biologics is significantly higher than that of small molecules in total, in alliances, and in financing, suggesting that inter-firm transactions for biologic cancer drugs actively occur through various means. Additionally, a positive and significant correlation exists between the number of transactions and the average number of approved indications for biologics, but not for small molecules. These results suggest that the observed trend of active inter-firm transactions is key in increasing the probability of success in cancer drug research and development. This could provide a potential breakthrough in this industry for the successful development of innovative drug candidates to address unmet medical needs. Further study is necessary to confirm the applicability of this paradigm in broader drug discoveries and development.